Status: Recruiting
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic solid tumors. ODC-IL2 is a conditionally activated IL-2 prodrug and will be administered as a single agent via intravenous infusion on Days 1 and 15 of a 28-day cycle. Up to approximately 50 patients will be enrolled in this study.
Participants needed: 50
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Trutino Biosciences Inc.Updated: Jan 13, 2025Locations: 1
Eligibility criteria
Histologically or cytologically confirmed advanced or metastatic solid tumors, f... [+12]
New York Heart Association Class III or IV, cardiac disease, myocardial infarcti... [+16]